DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the publication of an article in the online journal BMC Molecular Biology supporting the Company’s novel method of stimulating the CD40 receptor signal cascade in dendritic cells (DCs), which may potentially improve the potency of their DC-based immunotherapy. Argos’ process involves electroporation of RNA into DCs, encoding a modified version of the T-cell protein CD40L. Stimulating this receptor signal cascade through ectopic expression of this novel CD40L RNA results in secretion of the downstream inflammatory cytokine IL-12 from the electroporated DCs. This new approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
